Refine
Document Type
- Article (4) (remove)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- ATO (1)
- Bevacizumab (1)
- Capecitabine (1)
- IGF (1)
- NOTCH1 (1)
- Oxaliplatin (1)
- Preoperative radiochemotherapy (1)
- Rectal cancer (1)
- SHH (1)
- WNT (1)
Institute
- Medizin (2)
Der Langstielige Mannsschild (Androsace elongata) gehört zu den auch früher schon sehr seltenen Pflanzenarten Hessens und wurde erstmals Anfang des 19. Jahrhunderts nachgewiesen. Weitere Nachweise gelangen danach erst ab etwa 1950. Seither wurde die Art im Raum Münzenberg in der nördlichen Wetterau kontinuierlich bestätigt. Im Rahmen der 2008 durchgeführten Untersuchungen konnten zwei weitere Wuchsorte aufgefunden werden. Keines dieser Vorkommen unterliegt bislang gesetzlichem Schutz. Die wenigen Pflanzen an stärker geneigten Böschungen sind durch Sukzession hochgradig bedroht und auf den geringer geneigten Wuchsflächen können die individuenreicheren Bestände bei Ausbleiben oder Änderung der derzeitigen Nutzung rasch zusammenbrechen. Als geeignete Maßnahme zur Erhaltung bietet sich die Einbeziehung aller Flächen in die auf anderen Magerrasen der Umgebung schon praktizierte Huteschäferei an.
Within the scope of the Wildlife Conservation Programme of the Botanical Society for the Nature Conservation in Hesse, a comprehensive survey was carried out of a comparatively common species, the Common Pasque Flower (Pulsatilla vulgaris). It still occurs in large populations on the nutrient poor chalk meadows of the Vorderhoen and Kuppenhoen. Other populations are known from the Wetterau and the Schluechterner Becken. A few other populations are known, but they only have a few individuals. Altogether 64 populations were recorded, five with more than 1,000 plants. The largest population, with over 50,000 individuals, is in the Weinberg nature reserve, Molzbach (near Huenfeld).
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%. We conducted a single arm phase II study to investigate the feasibility and efficacy of addition of bevacizumab and oxaliplatin to preoperative standard RCT with capecitabine.
Methods: Eligible patients had LARC (cT3-4; N0/1/2, M0/1) and were treated with preoperative RCT prior to planned surgery. Patients received conventionally fractionated radiotherapy (50.4 Gy in 1.8 Gy fractions) and simultaneous chemotherapy with capecitabine 825 mg/m2 bid (d1-14, d22-35) and oxaliplatin 50 mg/m2 (d1, d8, d22, d29). Bevacizumab 5 mg/kg was added on days 1, 15, and 29. The primary study objective was the pCR rate.
Results: 70 patients with LARC (cT3-4; N0/1, M0/1), ECOG < 2, were enrolled at 6 sites from 07/2008 through 02/2010 (median age 61 years [range 39–89], 68% male). At initial diagnosis, 84% of patients had clinical stage T3, 62% of patients had nodal involvement and 83% of patients were M0. Mean tumor distance from anal verge was 5.92 cm (± 3.68). 58 patients received the complete RCT (full dose RT and full dose of all chemotherapy). During preoperative treatment, grade 3 or 4 toxicities were experienced by 6 and 2 patients, respectively: grade 4 diarrhea and nausea in one patient (1.4%), respectively, grade 3 diarrhea in 2 patients (3%), grade 3 obstipation, anal abscess, anaphylactic reaction, leucopenia and neutropenia in one patient (1.4%), respectively. In total, 30 patients (46%) developed postoperative complications of any grade including one gastrointestinal perforation in one patient (2%), wound-healing problems in 7 patients (11%) and bleedings in 2 patients (3%). pCR was observed in 12/69 (17.4%) patients. Pathological downstaging (ypT < cT and ypN ≤ cN) was achieved in 31 of 69 patients (44.9%). All of the 66 operated patients had a R0 resection. 47 patients (68.1%) underwent sphincter preserving surgery.
Conclusions: The addition of bevacizumab and oxaliplatin to RCT with capecitabine was well tolerated and did not increase perioperative morbidity or mortality. However, the pCR rate was not improved in comparison to other trials that used capecitabine or capecitabine/oxaliplatin in preoperative radiochemotherapy.
Ceritinib-induced regression of an insulin-like growth factor-driven neuroepithelial brain tumor
(2019)
The insulin-like growth factor (IGF) pathway plays an important role in several brain tumor entities. However, the lack of inhibitors crossing the blood–brain barrier remains a significant obstacle for clinical translation. Here, we targeted the IGF pathway using ceritinib, an off-target inhibitor of the IGF1 receptor (IGF1R) and insulin receptor (INSR), in a pediatric patient with an unclassified brain tumor and a notch receptor 1 (NOTCH1) germline mutation. Pathway analysis of the tumor revealed activation of the sonic hedgehog (SHH), the wingless and integrated-1 (WNT), the IGF, and the Notch pathway. The proliferation of the patient tumor cells (225ZL) was inhibited by arsenic trioxide (ATO), which is an inhibitor of the SHH pathway, by linsitinib, which is an inhibitor of IGF1R and INSR, and by ceritinib. 225ZL expressed INSR but not IGF1R at the protein level, and ceritinib blocked the phosphorylation of INSR. Our first personalized treatment included ATO, but because of side effects, we switched to ceritinib. After 46 days, we achieved a concentration of 1.70 µM of ceritinib in the plasma, and after 58 days, MRI confirmed that there was a response to the treatment. Ceritinib accumulated in the tumor at a concentration of 2.72 µM. Our data suggest ceritinib as a promising drug for the treatment of IGF-driven brain tumors.